1-Benzyl-4-cinnamoyl-piperazin | 56303-17-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 1-Benzyl-4-cinnamoyl-piperazin
• 英文别名: N¹-Benzyl-N⁴-cinnamoyl-piperazin；1-benzyl-4-(3-phenyl-acryloyl)-piperazine；1-(4-Benzylpiperazin-1-yl)-3-phenylprop-2-en-1-one
• CAS: 56303-17-4
• 化学式: C₂₀H₂₂N₂O
• mdl: MFCD01480602
• 分子量: 306.407
• InChiKey: GWHWSKGIRYVYDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (Z)-(6-methoxy-(E)-2-styrylbenzo[b]furo[3,2-d][1,3]oxazin-4-ylideno)acetaldehyde 、 1-苄基哌嗪 以 甲苯 为溶剂， 以86%的产率得到1-Benzyl-4-cinnamoyl-piperazin
  参考文献：
  名称：

  A Novel One-Step Synthesis of Benzo[b]furo[3,2-b]pyridines Having an Amino Group at the 4-Position from Benzo[b]furo[3,2-d][1,3]oxazine

  摘要：

  A novel one-step synthesis of benzo[b]furo[3,2-b]pyridines having an amino group at the 4-position from benzo[b]furo[3,2-d][1,3]oxazine by treatment of various amines is described.

  DOI：

  10.3987/com-12-12615

文献信息

• [EN] AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE<br/>[FR] INHIBITEURS DE L'AUTOTAXINE CONTENANT UN NOYAU À CYCLE BENZYLE-AMIDE CYCLIQUE HÉTÉROAROMATIQUE
  申请人：NOVARTIS AG

  公开号：WO2015008230A1

  公开（公告）日：2015-01-22

  The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

  本发明涉及新型化合物，这些化合物是自体磷脂酶抑制剂，涉及它们的制备方法，含有它们的药物组合物和药物，以及它们在由自体磷脂酶介导的疾病和紊乱中的应用。
• 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
  申请人：Bollbuck Birgit

  公开号：US20060173004A1

  公开（公告）日：2006-08-03

  A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.

  式(I)的化合物，或其药学上可接受的盐或酯，其中符号的含义如定义所示，它们是CCR-1的拮抗剂，并且在药学上用于治疗CCR-1参与的疾病和情况，例如炎症性疾病。
• AUTOTAXIN INHIBITORS
  申请人：BEATTIE David

  公开号：US20160184318A1

  公开（公告）日：2016-06-30

  The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

  本发明涉及新型的自体磷脂酰肌醇酰化酶抑制剂化合物，其制备方法，包含它们的药物组合物和药物以及它们在由自体磷脂酰肌醇酰化酶介导的疾病和障碍中的应用。
• EBI2 MODULATORS
  申请人：SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE

  公开号：US20160214951A1

  公开（公告）日：2016-07-28

  Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.

  本文提供了小分子埃普斯坦-巴尔病毒诱导的G蛋白偶联受体2（EBI2）调节剂化合物，包括这些化合物的组合物，以及使用这些化合物和组合物的方法。EBI2是治疗多种疾病或病症的治疗靶点。在某些实施例中，EBI2是治疗自身免疫性疾病或病症、癌症和心血管疾病等疾病或病症的治疗靶点。
• Autotaxin inhibitors
  申请人：Novartis AG

  公开号：US10183025B2

  公开（公告）日：2019-01-22

  The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

  本发明涉及作为自体舒缩素抑制剂的新型化合物、其制备工艺、含有它们的药物组合物和药品，以及它们在自体舒缩素介导的疾病和失调中的用途。